New combo therapy for advanced melanoma enters early human testing
NCT ID NCT03021460
First seen Jan 22, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—in 20 people with advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system attack cancer cells, while ibrutinib blocks enzymes that help tumors grow. The study aims to find the highest safe dose and see if the combination can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and ibrutinib (Imbruvica)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced melanoma that cannot be surgically removed.
What could go wrong
This is a very early (Phase I) trial with only 20 participants, so the main goal is safety and dosing, not proof of effectiveness. The combination may cause significant side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.